MetLife Investment Management’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $485K | Sell |
65,315
-6,419
| -9% | -$67.5K | ﹤0.01% | 1763 |
|
|
2025
Q4 | $844K | Buy |
71,734
+1,524
| +2% | +$16.4K | ﹤0.01% | 1524 |
|
|
2025
Q3 | $542K | Sell |
70,210
-6,002
| -8% | -$42K | ﹤0.01% | 1768 |
|
|
2025
Q2 | $557K | Hold |
76,212
| – | – | ﹤0.01% | 1625 |
|
|
2025
Q1 | $723K | Sell |
76,212
-1,191
| -2% | -$14.9K | ﹤0.01% | 1523 |
|
|
2024
Q4 | $1.28M | Buy |
77,403
+2,596
| +3% | +$40.3K | 0.01% | 1296 |
|
|
2024
Q3 | $1.1M | Hold |
74,807
| – | – | 0.01% | 1340 |
|
|
2024
Q2 | $1.04M | Buy |
74,807
+7,465
| +11% | +$106K | 0.01% | 1326 |
|
|
2024
Q1 | $1.06M | Hold |
67,342
| – | – | 0.01% | 1265 |
|
|
2023
Q4 | $1.09M | Hold |
67,342
| – | – | 0.01% | 1252 |
|
|
2023
Q3 | $828K | Hold |
67,342
| – | – | 0.01% | 1343 |
|
|
2023
Q2 | $1.08M | Buy |
67,342
+906
| +1% | +$14.9K | 0.01% | 1226 |
|
|
2023
Q1 | $1.16M | Hold |
66,436
| – | – | 0.01% | 1156 |
|
|
2022
Q4 | $614K | Buy |
66,436
+1,124
| +2% | +$10.5K | ﹤0.01% | 1513 |
|
|
2022
Q3 | $562K | Buy |
65,312
+3,803
| +6% | +$37.8K | ﹤0.01% | 1554 |
|
|
2022
Q2 | $501K | Hold |
61,509
| – | – | ﹤0.01% | 1658 |
|
|
2022
Q1 | $747K | Buy |
61,509
+22,424
| +57% | +$472K | ﹤0.01% | 1516 |
|
|
2021
Q4 | $1.33M | Hold |
39,085
| – | – | 0.01% | 1015 |
|
|
2021
Q3 | $1.89M | Sell |
39,085
-1,733
| -4% | -$80.2K | 0.02% | 882 |
|
|
2021
Q2 | $1.84M | Hold |
40,818
| – | – | 0.02% | 912 |
|
|
2021
Q1 | $1.97M | Sell |
40,818
-1,897
| -4% | -$98.8K | 0.02% | 878 |
|
|
2020
Q4 | $2.3M | Sell |
42,715
-3,060
| -7% | -$138K | 0.02% | 757 |
|
|
2020
Q3 | $1.69M | Hold |
45,775
| – | – | 0.02% | 792 |
|
|
2020
Q2 | $1.42M | Buy |
45,775
+5,912
| +15% | +$164K | 0.02% | 879 |
|
|
2020
Q1 | $1.1M | Sell |
39,863
-2,300
| -5% | -$68.9K | 0.02% | 863 |
|
|
2019
Q4 | $1.23M | Hold |
42,163
| – | – | 0.01% | 990 |
|
|
2019
Q3 | $806K | Buy |
42,163
+2,474
| +6% | +$58K | 0.01% | 1171 |
|
|
2019
Q2 | $871K | Buy |
39,689
+3,051
| +8% | +$67K | 0.01% | 1173 |
|
|
2019
Q1 | $750K | Buy |
36,638
+10,141
| +38% | +$176K | 0.01% | 1212 |
|
|
2018
Q4 | $334K | Hold |
26,497
| – | – | ﹤0.01% | 1612 |
|
|
2018
Q3 | $407K | Hold |
26,497
| – | – | ﹤0.01% | 1661 |
|
|
2018
Q2 | $347K | Hold |
26,497
| – | – | ﹤0.01% | 1630 |
|
|
2018
Q1 | $216K | Hold |
26,497
| – | – | ﹤0.01% | 1846 |
|
|
2017
Q4 | $235K | Buy |
+26,497
| New | +$244K | ﹤0.01% | 1848 |
|
Other funds holding NEO
FLAM
GF
VPM
VCM
B
MetLife Investment Management's NEO Position: Q1 2026 in Review
MetLife Investment Management reduced its NeoGenomics (NEO) stake by 8.9% in Q1 2026, selling an estimated $67.5K and leaving 65,315 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #1763.
MetLife Investment Management first reported a position in NEO in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.3M in Q4 2020. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.
- MetLife Investment Management held 65,315 shares of NeoGenomics worth $485K as of Q1 2026.
- MetLife Investment Management sold 6,419 NeoGenomics shares in Q1 2026, an estimated $67.5K.
- NeoGenomics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1763 holding.
- MetLife Investment Management first reported a position in NeoGenomics in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's NeoGenomics position peaked at $2.3M in Q4 2020.
- 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.